Accordingly, the ability of metformin to downregulate histone H3K4 methyltransferase in lung cancer cells could be independent of AMPK activation despite the contribution of the AMPK/mTOR signaling pathway to metformin-induced anticancer therapy. Here, MTOR is linked to lung carcinoma.